Pfizer (BUE:PFE) Cyclically Adjusted Revenue per Share: ARS4,462.72 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:PFE Pfizer Inc BUE:PFE
58 GF Score
Price ARS9,825.00
GF Value ARS10,165.01
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Cyclically Adjusted Revenue per Share?

Pfizer BUE:PFE +1.50% 58 Cyclically Adjusted Revenue per Share is ARS4,462.72 as of Mar. 2026. GuruFocus rates BUE:PFE with a GF Score™ of 58/100 and a GF Value™ of ARS10,165.01 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pfizer's adjusted revenue per share for the three months ended in Mar. 2026 was ARS7,051.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS4,462.72 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pfizer's average Cyclically Adjusted Revenue Growth Rate was 3.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pfizer was 13.90% per year. The lowest was -0.10% per year. And the median was 5.20% per year.

As of today (2026-07-17), Pfizer's current stock price is ARS9825.00. Pfizer's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ARS4,462.72. Pfizer's Cyclically Adjusted PS Ratio of today is 2.20.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 6.59. The lowest was 1.85. And the median was 4.02.


Pfizer  (BUE:PFE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pfizer's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9825.00/4462.72
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 6.59. The lowest was 1.85. And the median was 4.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pfizer Cyclically Adjusted Revenue per Share Related Terms


Pfizer Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pfizer's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Cyclically Adjusted Revenue per Share Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 937.33 1,839.34 5,443.14 3,450.09 4,571.08

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,885.58 3,629.11 4,617.48 4,571.08 4,462.72

BUE:PFE vs GILD, BMY, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PS Ratio falls into.


BUE:PFE
58GF Score
Pfizer Inc BUE:PFE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pfizer's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=7051/330.2130*330.2130
=7,051.000

Current CPI (Mar. 2026) = 330.2130.

Pfizer Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 59.779 241.018 81.902
201609 63.281 241.428 86.553
201612 70.705 241.432 96.705
201703 64.680 243.801 87.605
201706 70.442 244.955 94.960
201709 76.394 246.819 102.206
201712 86.342 246.524 115.653
201803 85.865 249.554 113.618
201806 112.850 251.989 147.882
201809 163.499 252.439 213.871
201812 14.728 251.233 19.358
201903 178.359 254.202 231.692
201906 208.964 256.143 269.391
201909 251.068 256.759 322.894
201912 39.134 256.974 50.287
202003 222.998 258.115 285.287
202006 240.359 257.797 307.877
202009 270.891 260.280 343.675
202012 328.481 260.474 416.428
202103 461.887 264.877 575.819
202106 630.610 271.696 766.429
202109 821.010 274.310 988.328
202112 834.743 278.802 988.669
202203 957.025 287.504 1,099.192
202206 1,168.836 296.311 1,302.567
202209 1,100.227 296.808 1,224.055
202212 1,466.974 296.797 1,632.139
202303 1,275.262 301.836 1,395.155
202306 1,092.750 305.109 1,182.660
202309 1,672.521 307.789 1,794.373
202312 1,847.478 306.746 1,988.816
202403 4,400.462 312.332 4,652.388
202406 4,176.589 314.175 4,389.795
202409 5,898.265 315.301 6,177.220
202412 6,292.001 315.605 6,583.231
202503 5,121.085 319.799 5,287.849
202506 6,097.626 322.561 6,242.278
202509 7,916.114 324.800 8,048.041
202512 8,907.302 324.054 9,076.595
202603 7,051.000 330.213 7,051.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ARS4,462.72 mean?
Pfizer (BUE:PFE) has a Cyclically Adjusted Revenue per Share of ARS4,462.72 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors.
Is Pfizer's Cyclically Adjusted Revenue per Share too high?
Pfizer's current Cyclically Adjusted Revenue per Share is ARS4,462.72. Overall, Pfizer has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Cyclically Adjusted Revenue per Share compare to GILD and BMY?
Pfizer's Cyclically Adjusted Revenue per Share of ARS4,462.72 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors. Pfizer's current Cyclically Adjusted Revenue per Share is ARS4,462.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (BUE:PFE) is currently considered Fairly Valued. The stock's GF Value™ is ARS10,165.01, compared to a current price of ARS9,825.00 — trading 3.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ARS4,462.72. Pfizer's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pfizer (BUE:PFE), the current Cyclically Adjusted Revenue per Share is ARS4,462.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (BUE:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of ARS9,825.00 is trading 3.3% below its estimated GF Value™ of ARS10,165.01. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for BUE:PFE:

  • Cyclically Adjusted Revenue per Share: ARS4,462.72
  • GF Value™: ARS10,165.01 vs. price of ARS9,825.00 (3.3% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the BUE:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
58GF Score

Get the complete analysis for BUE:PFE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS9,825.00
Price
ARS10,165.01
GF Value